Mortality, intensive care treatment, and cost evaluation: Role of a polymerase chain reaction assay in patients with sepsis.

J Int Med Res · 2018 · PMC6011302 · PMID 28730906

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.9900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

The cost difference between 7 days of antimicrobial therapy with and without the cost of the SF assay did not reach statistical significance in the SF+ group (322 EUR [range, 162–336 EUR] vs. 472 EUR [range, 308–476 EUR]; p = 0.09) but was statistically significant in the SF− group (320 EUR [range, 160–380 EUR] vs. 472 EUR [range, 308–476 EUR]; p < 0.001).

also in 111,027 other papers

showed a trendp > 0.99not close (p > 0.1)

However, the SF+ group showed a trend toward a higher 6-month mortality rate (SF+, 60%; SF−; 57%; p > 0.99), 1-year mortality rate (SF+, 80%; SF−, 66%; p = 0.47), and 2-year mortality rate (SF+, 80%; SF−, 70%; p = 0.70).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.